A Phase 1,Single-center,Open-label Study Investigating the Mass Balance,Pharmacokinetics and Metabolism of [14C]XZP-3621 in Healthy Male Subjects
Latest Information Update: 04 May 2023
At a glance
- Drugs XZP-3621 (Primary)
- Indications Cancer; Non-small cell lung cancer
- Focus Pharmacokinetics
- Sponsors Xuanzhu Biopharmaceutical
Most Recent Events
- 04 May 2023 New trial record